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Abstract Increasing prevalence of obesity in many parts
of the world emphasizes the importance of learning more
about the relationship between obesity and prostate cancer
(PC). The present paper reviews the impact of obesity on
PC using knowledge obtained from the available literature.
Search of published literature in PUBMED database. Adi-
pose tissue constitutes an active endocrine and metabolic
organ which may be relevant in the development and pro-
gression of PC by diVerent potential mechanisms. Further-
more, obesity could have an impact on the outcome of
diVerent treatment modalities for PC, both functionally as
anatomically. Obesity is a growing problem, however, the
exact role in the development and progression of PC has
not been elucidated. Regarding the optimal treatment of PC
in obese patients, comparative prospective studies are
needed.
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Introduction
Obesity is one of the most challenging and growing health
problems in industrialized countries. In Europe, the preva-
lence of obesity has more than doubled during the last two
decades. According to the World Health Organization
(WHO), obesity is deWned as body mass index (BMI,
weight in kilograms divided by height in meters squared,
kg/m2) over 30 kg/m2. At present, more than half of all
adults are categorized as having overweight (BMI, between
25 and 30 kg/m2), and up to 30% is obese (BMI > 30 kg/
m2) [1]. However, currently, there is no universally
accepted measurement of obesity. BMI and waist-to-hip
ratio (WHR) are the most common anthropometric methods
used in clinical practice. Since abdominal visceral adipo-
cytes are more metabolically active than abdominal subcu-
taneous adipocytes, one of the limitations of BMI is that it
could be a less valid indicator of adiposity among the eld-
erly, who tend to have a shift of fat from peripheral to cen-
tral sites with an increase in WHR at a constant level of
BMI [2]. More precisely WHR measures abdominal adi-
pose tissue (or circumference) and fat distribution. The
waist is deWned as the abdominal circumference midway
between costal margin and the crest of the iliac. The largest
circumference just below the iliac crest is deWned as the
hip. For men a WHR > 0.90 is a fairly accurate determina-
tion of an increased risk for obesity-related events.
Obesity is associated with numerous conditions that
includes hypertension, high glucose levels, dyslipidemia,
and central adiposity. This cluster of conditions refers to
the metabolic syndrome [3]. This metabolic syndrome is
accompanied by numerous chronic diseases, including
hypertension, coronary artery disease, asthma, diabetes and
arthritis, having a great impact on general health systems
[4]. In addition to its link to several chronic medical condi-
tions, obesity has also been associated with increased death
rates of several types of cancer [5]. High prevalence of
prostate cancer (PC) and increasing prevalence of obesity
in many parts of the world, emphasizes the importance of
learning more about the relationship between obesity and
PC.
This review will look at the relationship between obesity
and PC. Firstly, we brieXy describe some of the hormonal
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mechanisms aVecting the prostate. Secondly, we review
and discuss potential links between obesity and the devel-
opment and detection of PC. Finally, the impact of obesity
are summarized on surgical outcomes, and biochemical
recurrence, following prostate surgery.
Potential biochemical mechanisms aVecting the 
developing of prostate cancer
Adipose tissue actually is an active endocrine and meta-
bolic organ, which could inXuence PC on several ways.
First, PC is a sex steroid sensitive disease. Obesity has
an important impact on the synthesis and bioavailability of
endogenous sex steroids and is associated with increased
serum estradiol and decreased serum concentrations of free
testosterone. Increased levels of estradiol are caused by
peripheral conversion of testosterone to estradiol by
increased aromatase activity secondary to the accumulation
of adipose tissue. Obesity also reduces the concentrations
of sex-hormone-binding globulin (SHBG). Both phenom-
ena increase the fraction of bioavailable estradiol and lead
to a reduction in total testicular testosterone production [2,
6]. At Wrst sight this might seem protective for PC. How-
ever, reports have shown that a lower preoperative total tes-
tosterone correlated with a poorer pathological stage at time
of surgery [7, 8]. Also, a large pooled case control prospec-
tive study found a modest, but signiWcant decrease in PC
risk for increasing levels of total testosterone [9].
In an experimental study, prenatal exposure to an
extreme low dose of diethylstilbestrol (DES) and other
estrogenic compounds signiWcantly aVects the development
of mouse prostate in the presence of androgen. Another pre-
liminary report suggests that oVspring of DES-exposed
mothers have a higher risk of prostate cancer [10].
Together, although estrogen is used as an anti-androgen in
the treatment of advanced PC, these data suggest that estro-
gens may enhance the risk of PC earlier in life.
Second, beyond alterations in sex steroid hormones,
obesity is also associated with increased levels of several
other serum hormones, such as leptin, insulin and insulin-
like growth factor-1 (IGF-1). Leptin, an obesity related hor-
mone, is produced by adipocytes and plays a major role in
controlling body weight homeostasis and is directly related
to the degree of obesity. However, leptin receptors also
have been identiWed in the prostate gland, suggesting a
plausible biological role in this gland [11]. Recently, leptin
has been shown to stimulate the in-vitro growth of hormone
refractory PC cell lines [12, 13]. In both reports leptin
caused signiWcant proliferation in both the PC-3 and
DU145 cell lines when compared with untreated control
cells. Clinical studies looking at the relation between leptin
and PC are not consistent. A Chinese case-control study
reported an increased risk of PC, but the trends were not
statistically signiWcant [14]. After adjustment for age, the
men in the highest tertile of leptin levels had an approxi-
mately twofold risk of PC (Odds ratio, OR = 1.78, 95%
CI = 1.07–2.95). Albeit a Norwegian case-control study
found no support for this hypothesis (OR = 0.9, 95%
CI = 0.6–1.6) [15]. Although the risk for PC in individuals
with higher levels of leptin is not clearly proven, some
studies showed that higher levels of leptin were linked to
tumour progression and advanced disease. Saglam et al.
[16] noticed in a cross-sectional study that elevated leptin
was signiWcantly associated with poorly diVerentiated can-
cer and extraprostatic cancer. Chang et al. [17] reported
men with elevated plasma leptin concentrations had an
increased risk of being diagnosed with high-volume PC that
was attenuated after adjustment for BMI (OR = 2.41, 95%
CI = 0.93–4.58). One study did not Wnd an relation between
serum leptin and pathological stage (pT3a). However this
study was done in predominantly white men with mainly
low risk disease (OR = 1.14, 95% CI = 0.76–1.71) [18]. In
all, these observations suggest that leptin may play no role
in initiation of PC but may play some part in the progres-
sion of PC.
Diabetes mellitus (non-insulin dependent, type-II) and
obesity are common conditions which are components of
the same metabolic syndrome. In obesity, diVerent endo-
crine and metabolic signals lead to insulin resistance,
resulting in a chronic compensatory hyperinsulinaemia and
increased levels of bioavailable IGF-1. In their turn, insulin
and IGF-1 promote cellular proliferation and inhibit apop-
tosis in many tissue types [5]. These eVects may be respon-
sible for tumorgenesis of PC in obese patients. In an in-
vitro study a signiWcantly lower proliferation rate of andro-
gen-independent PC-3 prostate cells was seen in IGF-1
deWcient hosts in comparison to IGF-1 expressing hosts
[19]. In addition, several prospective cohort and case-con-
trol studies have shown positive associations between PC
risk and circulating IGF-1 level in men [20–22]. In these
studies the OR varied between 1.63 (95% CI = 0.92–2.89)
and 4.3 (95% CI = 1.8–10.6) for men in the highest quartile
of IGF-I.
In summary, possible mechanisms by which obesity may
impact upon PC include altered serum steroid hormones,
leptin, insulin and IGF-1, levels. Most studies of hormone
levels and PC risk have evaluated each hormone individu-
ally. DiYculties comparing these studies are caused by
complex interrelationships between hormones, binding pro-
teins and their receptors and the moment of exposure. In
addition, most studies on obesity usually reXect an one-
moment evaluation, whereas the cumulative eVect of fat
content (all-life exposure) may be relevant in prostatic dis-
ease development.123
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Two large retrospective cohort studies found a positive
relation between BMI and PC. One among 135,000 Swed-
ish construction workers, reported a positive association of
BMI (>26.2 kg/m2) and risk of PC (RR = 1.13, 95%
CI = 0.99–1.29, P = 0.10) [23]. The association between
BMI and PC was stronger when looking at mortality than at
incidence (RR = 1.40, 95% CI = 1.09–1.81, P = 0.04). The
other, a large Norwegian cohort study of 950,000 men,
reported an increasing risk of PC with increasing BMI in
men having a BMI below 35.0 kg/m2 (RR = 1.15, 95%
CI = 1.03–1.28) [24]. Interestingly, higher obesity-associ-
ated risk was seen in those being youngest with an age
between 20 and 29 years at measurement. On the other
hand, two more recent case-control studies addressed a pro-
tective association between obesity and PC risk [25, 26].
The age adjusted odds ratios ranged from 0.78 (95%
CI = 0.56–1.09) to 0.91 (95% CI = 0.66–1.21). Finally,
another recent prospective population-based cohort study
even found no association [27]. It should be noted that non-
biological explanations may contribute to the apparent dis-
parate results among epidemiological studies. For example,
some studies were done before the PSA era, diVerent BMI
categorizations were used, and study populations diVered in
sample size.
Another problem is that most of these studies have been
focused on obesity late in life, which may have another
impact on PC than obesity early in life. In the study of Rob-
son et al. [28] for example, men having obesity between the
ages of 20 and 29 years were less prone to develop PC
(OR = 0.36 95% CI = 0.18–0.71) than nonobese men. The
Health Professionals Follow-up, a prospective cohort study
of 51,529 U.S. patients, also addressed the eVect of obesity
before age 30 and found an inverse relation as well
(RR = 0.52 95% CI = 0.33–0.83) [29]. These analyses sup-
port the concept that the preadult hormonal milieu might be
important to PC risk. However, an Australian population-
based, case-control study, with 1.476 cases and 1.409 con-
trols, reported no association between BMI at age 21 and
the risk of developing PC later in life [30]. These discrep-
ancy can be caused due to diVerent cutpoints used to deWne
large body size and the use of diVerent study populations
(American vs. Australian).
Another diYculty comparing above-mentioned epidemi-
ologic studies is that they usually consider PC as one bio-
logic entity when it is very likely that PC is biologically
heterogeneous, not only in terms of grade and stage but also
in respect to its clinical behaviour [31].
In summary, although a link between obesity and the
development of PC could be expected based on endocrine
changes, the results of large studies were inconsistent due
to methodological problems. Unfortunately they do not
permit deWnitive conclusions and it demonstrates the diY-
culty to interpret the epidemiologic data when it comes to
obesity and PC risk. However, there is a suggestion that
obesity early in life decreases PC risk, where as obesity
later in life increases the risk.
The detection of prostate cancer in obese patients
Prostate needle biopsy based on abnormal digital rectal
examination (DRE) or elevated prostate speciWc antigen
(PSA) level, is the cornerstone in the detection of PC. Obvi-
ously, factors that alter PSA and, or DRE can inXuence the
detectability of PC, unrelated to cancer biology.
In obese patients it is more diYcult to perform a proper
DRE, so a palpable nodule can be missed. Nowadays, how-
ever, most PC are detected on biopsy following an abnor-
mal PSA. As PSA production is androgen-dependent, it
stands to reason that signiWcant changes in androgens,
which may result from obesity, could lower PSA without
aVecting the true incidence of PC. At the other hand, if
obesity would result in larger prostates, this would make
detection of a cancer at biopsy less likely, given an equal-
size tumour.
Freedland et al. [32] tested the hypothesis, that obesity
results in larger prostates and lower PSA levels, which
delays the biopsy indication, in 1,414 men undergoing radi-
cal prostatectomy (RP). Obesity was signiWcantly associ-
ated with increasing prostate weight, only in men younger
than 63 years old, while there was no signiWcant association
between BMI and PSA. Assuming equal PSA concentra-
tions the degree of prostatic enlargement in younger obese
in this study would be expected to result in a modest (20–
25%) decrease for detecting PC due to technical issues
relating to larger prostate size.
In a study of a referral-based biopsy population in the
United States, Presti et al. [33] clearly focused a relation
between BMI and PC detection on 787 patients. When
stratiWed by age, signiWcant higher detection rates were
seen in the normal BMI group, compared to the obese
group for men younger than 70 years (52 vs. 42%), more
likely because a normal BMI was associated with larger
tumour volume on the biopsy irrespective of age. Con-
versely, in a referral-based biopsy population from Asia,
consisting of 497 men, no signiWcant association between
BMI groups and PC detection was established [34]. DiVer-
ences in racial distribution, population selection, duration
of obesity, amount of biopsy cores and study size could
very well explain this disparity.
Alternatively obesity may inXuence cancer screening
behaviour, as shown for cervical and breast cancers [35].
DiVerences in PC screening behaviour may explain PC out-
comes in obese men. Two recent American studies found123
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PSA test than their counterparts in the healthy weight range
[36, 37]. In these studies the odds for obese men having a
PSA test was 1.26 (95% CI = 1.06–1.36) respectively, 1.37
(95% CI = 1.24–1.51) higher than the odds for normal
weight men.
In summary, although lower PSA levels and larger pros-
tates seen in obese patients may decrease the detection rate
of PC in obese men, on the other hand, they are more likely
to receive a PSA test. So, overall impact of obesity on PC
detection remains to be proved in clinical series.
InXuences of obesity on surgical outcome
It is generally held that obesity makes many urological pro-
cedures more technically challenging. In RP this, for exam-
ple, is the case for a higher likelihood of postoperative
complications such as postoperative incontinence or stric-
ture of the anastomosis. However, few data are available on
the exact impact of obesity on the diVerent surgical tech-
niques. Of the available studies many consists of a small
number of patients.
Only three reports investigated the impact of obesity and
postoperative incontinence [38–40]. These retrospective
studies reported no association between obesity and incon-
tinence. Of note, all studies used questionnaires to evaluate
the incontinence with a response rate of only 55 and 70%,
which may bias the results.
Three studies analysed the relation between obesity and
health related quality of life (HRQOL) before and after RP.
Two studies, with 422, respectively 672 men, concluded
that excess BMI did not cause a decrease in HRQOL after
RP [41, 42]. While a recent prospective study of 472 men
found that high BMI did adversely aVect HRQOL before
and after the RP [43]. Although the populations of the three
studies were approximately comparable with 20% obese
patients, use of diVerent questionnaires, regional variation
in practitioner expertise and patient factors may aVect these
outcomes.
Despite surgical techniques blood loss remains a com-
mon intraoperative complication associated with RP, mak-
ing a RP more diYcult. If obese patients lose more blood
during the operation, poorer vision may be one of the fac-
tors that obese patients are more prone to develop compli-
cations due to technical diYculty during the surgical
dissection. However, in only one retrospective analysis of
436 men, obese men were likely to lose signiWcant more
blood during a RP, compared to non-obese men [44].
An alternative method of approach for RP in obese
patients could be the perineal one. Three studies addressed
the feasibility of radical perineal prostatectomy in obese
patients. Small case series by Bockzo [45] and Dahm et al.
[46] consisted of 7 and 18 obese patients, respectively, have
suggested that perineal RP is both safe and feasible, not
only in obese, but also morbidly obese patients. The most
recent controlled study of 71 severely obese and 71 nonob-
ese patients, however, did Wnd an increased risk of both sur-
gical and anesthesia-related perioperartive complications,
e.g. laryngospasm requiring reintubation, myocardial
infarction, rectal injury and pulmonary edema [47].
Overall, a total of 12 complications (7 minor and 5 major)
occurred in the obese group and 5 (2 minor and 3 major)
occurred in the control group. This study did not provide
information about late complications and functional
outcomes.
The most recent surgical approach is laparoscopy. In a
prospective study no signiWcant diVerences were seen
between operative and peroperative morbidity in obese
patients who underwent a laparoscopic prostatectomy com-
pared to nonobese men [48]. Although prostatectomy in
obese patients was found more challenging due to the sig-
niWcant amount of intra-abdominal tissue, also the conti-
nence rate did not have any correlation with BMI or
prostate size. Except for a longer mean operative time in
obese patients, similar conclusions were reported by Brown
et al. [49] and Eden et al. [50].
Another form of laparoscopic surgery is robotic assisted
surgery. Two reports, showed the impact of obesity on
robotic assisted laparoscopic prostatectomy. In a prospective
study reported by Mikhail et al. [51] obesity did not increase
perioperative and postoperative morbidity, except for opera-
tive time and estimated blood loss. After 1 year of followup,
74% of the obese patients returned to baseline continence.
However, Ahlering et al. [52] reported signiWcantly more
complications in obese men and they required more time to
return to baseline urinary function. At 6 months only 47% of
obese patients had achieved urinary continence, which is low
compared to the report of Mikhail et al. [51] Maybe the
diVerent length of followup can explain the discrepancy of
the continence rate between both studies.
In summary, the surgical outcome of open RP indeed
seems to be worse in obese patients. Since this appears less
in laparoscopic RP, possible postoperative complications
can aVect the decision of choosing a therapy.
Biochemical recurrence after surgery in obese patients
Although the majority of men newly diagnosed with PC
will have early-stage disease, little is known about the
impact of obesity on oncological outcomes of primary ther-
apy for clinically localized disease. Compared to non-obese
men, two recent large American multi-institutional studies
addressed a signiWcant higher biochemical failure rate
among obese men treated with RP. In the study of Amling123
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and signiWcantly higher-grade cancers than those not con-
sidered obese. Interestingly, several racial observations
were made. In comparison with whites, blacks were signiW-
cantly more likely to be obese, had signiWcant higher PSA
levels, and had signiWcant higher-grade cancers. They were
also more likely to have positive surgical margins at the
time of RP. Overall, Univariate analysis, increasing BMI
and black race were both associated with higher PSA and
recurrence rates. In a multivariate analysis, however, only
black race remained a signiWcant independent predictor of
cancer recurrence. In the study of Freedland et al. [54] obes-
ity was also signiWcantly related to race. BMI, whether cate-
gorical or continuous, was a signiWcant predictor of
biochemical recurrence and was associated with higher-
grade tumours. During the study period of 15 years there
was a steady increase in mean BMI at time of surgery (from
26 to 28.5 kg/m2), however in the PSA era, no signiWcant
relationship between year of surgery and PSA failure was
seen. Although previous studies found a positive relation
between obesity and biochemical recurrence, Mallah and
co-workers [55], found a weak associations between disease
progression and increasing BMI, which was of negligible
prognostic value in men who received surgery. However,
the deWnition of disease progression used, as well as the sta-
tistical approach, makes their results hard to compare with
the previous mentioned reports. The results of these studies
clearly indicate that even if obesity has a relation with bio-
chemical progression, this is a multifactorial process.
There are some potential explanations for a higher bio-
chemical recurrence rate in obese men. Oefelen et al. found
intraoperative blood loss, which is likely to be more in
obese patients [44], as an independent risk factor for PC
recurrence [56]. This can be a causal relation, since periop-
erative transfusion with allogeneic blood may impair
immune response and has been proved to have a detrimen-
tal eVect on the recurrence of curable colorectal cancers
[57]. This also may play a role in the higher biochemical
failure rates seen in obese patients with PC. It is possible
that the tamponade eVect of the pneumoperitoneum and
magniWcation of the scope during laparoscopy in obese
patients may allow better hemostasis compared to the open
surgical approaches. However, despite the possible clinical
relevance, no comparing data are available.
Compared to non-obese, more positive surgical margins
were seen in obese men who underwent a RP [53, 54]. This
may be due to technical diYculty during the surgical dissec-
tion of the prostate among obese men. Higher rates of posi-
tive surgical margins could be responsible for the higher
PSA recurrence rate seen in obese patients. However, in a
study of 731 men who had an organ conWned disease and
negative surgical margins, the surgical technique was not
the only factor to explain the worse outcomes among obese
men, and the authors suggest that obesity was associated
with a biologically more aggressive form of PC [58].
In summary, various studies suggested that obesity may
result in a higher recurrence rates after RP. The question
remains, whether the diVerences in outcome are predomi-
nantly driven by worse biological features or technical diY-
culties during the surgical procedure.
Conclusion
Obesity is a growing problem in Western countries.
Autopsy studies from numerous countries worldwide, how-
ever, have shown similar rates of latent or clinically insig-
niWcant PC, despite markedly diVerent clinical signiWcant
PC and PC death rates among these populations [59, 60].
These Wndings suggest that although clinically insigniWcant
PC may be common to all races and ethnic groups, some as
yet unknown factor or factors may promote progression
into clinically signiWcant cancers. Recent international
trends show that PC incidence is increasing in low-inci-
dence countries such as China and Japan. At the same time
these countries are adopting westernised lifestyles associ-
ated with higher rates of obesity. These observations sug-
gest that there is a relation between obesity and PC. In any
case, epidemiological studies are showing conXicting
results between obesity and developing prostate diseases. In
contrast, more consistent Wndings have linked obesity with
PC mortality, advanced stage and higher gleason score.
Although any relation between obesity and PC remains
to be proven, more prospective studies are needed to exam-
ine the most optimal treatment modality, which means the
best oncological and functional results, for obese patients
suVering from PC.
In all, the relationship between obesity and prostate can-
cer is currently a hotly debated topic, but despite the num-
ber of publications devoted to the topic, the actual nature of
the relationship remains uncertain, and one should bear in
mind that obesity is a modiWable lifestyle factor.
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